


Read more  
about each  
activity or [see  
overview here](#)

## Executive Summary

# 9 activities for European Life Science actors

*- for long term collaboration and impact*



*Views and opinions expressed are, however, those of the author(s) only and do not necessarily reflect those of the European Union or EISMEA. Neither the European Union nor the granting authority can be held responsible for them.*

*Published June 2024 by the INNAXE consortium*



Funded by the  
European Union

# Introduction to Executive Summary


This Executive Summary aims to give a simple overview of how each of nine identified activities in the [INNAXE Joint Programme](#) potentially can impact four different target groups, representing the quadruple helix ecosystems of the Life Science Clusters.

Each activity is described and illustrated with the impact for each target group and its organisation.

**The 9 identified activities are:**


- 1 Acceleration of advanced therapies
- 2 Acceleration of medtech and digital health
- 3 Access to health data / secondary use of data
- 4 Cascade funding
- 5 Equity in health
- 6 Ecosystem positioning and community building
- 7 Support to attend international events
- 8 Matching innovators and investors
- 9 Public procurement and adoption of innovation

**Target groups / The quadruple helix**




# Impact Overview


Life Science companies




Universities and private research institutes



Healthcare operators



Patient associations



1. Acceleration of advanced therapies	Driving innovation and market growth	Speeding innovation and breakthroughs in research	Boosting efficiency and treatment success rates	Enhancing advocacy and treatment options
2. Acceleration of medtech and digital health	Boosting innovation and competitive edge	Advancing demand for new research	Cutting-edge treatments leading to better outcome for patients	Improving treatments
3. Access to health data / secondary use of data	Adding value to healthtech and life-science solutions, faster product development	Research can be transferred to commercial solutions, lower costs for research	Decision support, increased efficiency, and improved outcomes for patients	Personalized health and Improved preventive and early warning services.
4. Cascade funding	New business areas and new solutions	Increasing demand for transfer of technology	Enhancing efficiency and outcome due to new innovative solutions	Better treatments
5. Equity in health	Driving business innovation and rethinking of solutions	Increasing demand for new research	Better health outcomes, economic savings, social justice and resilience	Fair access to resources and improved outcomes for all members.
6. Ecosystem positioning and community building	Linking to healthcare operators, research, and patient associations	Linking to companies and healthcare operators	Transfer of needs to researchers and companies	Lobby opportunity and contribution to needs analysis.
7. Support to attend international events	International exposure and enhancing cross cluster ecosystems collaboration	Linking to international ecosystems of companies and healthcare operators	International outreach leading to better solutions and pricing models	Improved healthcare services
8. Matching innovators and investors	Increasing development and maturation of new solutions to market	Enhancing spin-out and tech-transfer	New innovative solutions, increasing efficiency and patient outcome	Novel technologies improving treatment options
9. Public procurement and adoption of innovation	Increase investment in innovation	Leverage demand for tech-transfer	Improve efficiency and/or outcome due to new innovative technologies	Better healthcare

# 1 Acceleration of advanced therapies


*Accelerating advanced therapies by promoting regional ATMP players, providing market insights, showcasing successes, building a global community, and raising investments.*

Life Science  
companies




Driving innovation  
and market  
growth

Universities and  
private research  
institutes




Speeding  
innovation and  
breakthroughs in  
research

Healthcare  
operators



Boosting efficiency  
and treatment  
success rates

Patient  
associations



Enhancing  
advocacy and  
treatment options

# 2

## Acceleration of medTech and Digital Health

*Accelerate MedTech and digital health solutions through global collaboration, nurturing start-ups, fostering stakeholder partnerships, and addressing critical healthcare challenges.*

Life Science  
companies





Boosting innovation  
and competitive  
edge

Universities and  
private research  
institutes




Advancing demand  
for new research

Healthcare  
operators



Cutting-edge  
treatments leading  
to better outcome  
for patients

Patient  
associations



Improving  
treatments

# 3

## Access to health data


*Create conditions for leveraging health data in R&D&I by ensuring data provenance, prioritizing patient-centered care, and promoting EU standards.*

Life Science  
companies




Adding value to healthtech and life-science solutions, faster product development

Universities and  
private research  
institutes




Research can be transferred to commercial solutions, lower costs for research

Healthcare  
operators



Decision support, increased efficiency, and improved outcomes for patients.

Patient  
associations



Personalized health and Improved preventive and early warning services.

# 4


## Cascade funding

*Enhance INNAXE ecosystems by leveraging EU cascade funding for SMEs. Strengthen alliances, support health tech innovation, and simplify funding access.*


Life Science  
companies




Universities and  
private research  
institutes



Healthcare  
operators



Patient  
associations



New business  
areas and new  
solutions

Increased  
demand for  
transfer of  
technology

Improved  
efficiency or  
outcome due to  
new innovative  
technologies

Better  
treatments

# 5


## Equity in health

*INNAXE clusters integrates health equity in all activities, ensuring accessibility, quality, and fairness in healthcare for all, enhancing overall health outcomes.*


Life Science  
companies




Universities and  
private research  
institutes



Healthcare  
operators



Patient  
associations



Driving business  
innovation and  
rethinking of  
solutions

Linking to  
companies and  
healthcare  
operators

Better health  
outcomes,  
economic savings,  
social justice and  
resilience

Fair access to  
resources and  
improved outcomes  
for all members



# 6

## Ecosystem positioning & community building

*Enhance ecosystem positioning and community by building strategic partnerships, fostering knowledge exchange, supporting entrepreneurship, and promoting diversity within the Health and Life Sciences sectors.*


Life Science  
companies




Universities and  
private research  
institutes



Healthcare  
operators



Patient  
associations



Linking to  
healthcare  
operators,  
research, and  
patient  
associations

Linking to  
companies and  
healthcare  
operators

Transfer of needs  
to researchers and  
companies

Lobby opportunity  
and contribution to  
needs analysis

# 7

## Support to attend international events

*INNAXE clusters secure reduced rates and organize joint booths at key conferences, boosting visibility, networking, and value for members.*


Life Science  
companies




Universities and  
private research  
institutes



Healthcare  
operators



Patient  
associations



# 8



## Matching innovators and investors

*INNAXE aim to connect European start-ups with investors through a series of events, boosting investment opportunities and fostering innovation.*


Life Science  
companies




Universities and  
private research  
institutes



Healthcare  
operators



Patient  
associations



# 9


## Public procurement & adoption of innovation

*INNAXE aims to bridge the gap between innovation and adoption in healthcare by connecting clinical needs with tech solutions, piloting procurement models, and supporting SMEs.*


Life Science  
companies




Universities and  
private research  
institutes



Healthcare  
operators



Patient  
associations



Increased  
investment in  
innovation

Leverage demand  
for tech-transfer


Improve efficiency  
and/or outcome  
due to new  
innovative  
technologies

Better healthcare




# Innaxe

Inclusive and Aligned  
Innovation Agendas  
Across Europe



Funded by  
the European Union



HEALTH & LIFE SCIENCES  
CLUSTER



Danish  
Life Science  
Cluster



CEBR  
COUNCIL OF EUROPEAN BIOREGIONS